THE Therapeutic Goods
Administration has designated
Prizer’s Sutent (sunitinib maleate)
as an orphan drug.
Sutent is indicated for the
treatment of pancreatic
nuroendocrine tumours, and is
available in 12.5mg, 25mg,
37.5mg and 50mg capsules.
More info at www.tga.gov.au.The above article was sent to subscribers in Pharmacy Daily's issue from 13 May 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 13 May 10
THE Independent Pharmacies of Australia Group (IPA) revealed strategic plans for 2025 at its Impact Partnership Forum and held its awards gala in Melbourne last week.
THE Tasmanian Government announced on Fri new tighter regulations restricting the sale of nicotine-containing vapes to patients with a prescription from a GP or nurse practitioner.
STRONG growth in Australia has helped MedAdvisor Solutions achieve robust results for FY24, with a revenue increase of 24.6% on the previous corresponding period to $122.1 million.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.